论文部分内容阅读
目的:探讨牛磺酸上调基因1(taurine upregulated gene 1,TUG1)在弥漫性大B细胞淋巴瘤(diffuse large B-cell Lymphoma,DLBCL)患者组织标本中的表达,分析TUG1表达与DLBCL患者临床特征及其预后的关系。方法:收集108例2011年1月至2016年12月在西南医科大学附属第一医院血液科确诊为DLBCL初诊患者和同期47例反应性淋巴结增生(reactive lymphoid hyperplasia,RLH)患者的组织标本。通过qPCR方法检测DLBCL和RLH患者组织标本中TUG1的表达,采用Chi-Square检验、Kaplan-Meier法和单因素及多因素分析法分别分析TUG1表达水平与DLBCL患者临床病理特征的关系和影响DLBCL患者生存时间及预后的因素。结果:TUG1在DLBCL患者组织中的表达显著高于RLH患者(6.108±0.332 vs 1.231±0.095,P<0.01)。TUG1表达与DLBCL患者的疾病分期、肿瘤大小、B细胞症状、IPI指数、GCB亚型及化疗敏感性显著相关(均P<0.01);TUG1表达量、疾病分期及肿瘤大小是影响DLBCL患者总生存时间(overall survival,OS)的因素。TUG1表达、疾病分期、IPI指数和化疗敏感性是影响DLBCL患者预后的因素。结论:TUG1在DLBCL组织中高表达,是影响患者预后的独立因素,TUG1有可能成为DLBCL患者新的预后评估标志物和基因治疗DLBCL的潜在靶点。
OBJECTIVE: To investigate the expression of TUG1 in tissue samples of patients with diffuse large B-cell lymphoma (DLBCL), and to analyze the relationship between TUG1 expression and clinical features of patients with DLBCL And its prognosis. Methods: From January 2011 to December 2016, 108 cases of newly diagnosed patients with DLBCL and 47 patients with reactive lymphoid hyperplasia (RLH) were enrolled in the Department of Hematology, the First Affiliated Hospital of Southwest Medical University from January 2011 to December 2016. The expression of TUG1 in tissue samples of DLBCL and RLH patients was detected by qPCR method. The relationship between the expression of TUG1 and clinicopathological features of DLBCL patients was analyzed by Chi-Square test, Kaplan-Meier method and univariate and multivariate analysis respectively, Survival time and prognosis factors. Results: The expression of TUG1 in DLBCL patients was significantly higher than that in RLH patients (6.108 ± 0.332 vs 1.231 ± 0.095, P <0.01). TUG1 expression was significantly associated with disease stage, tumor size, B cell symptom, IPI index, GCB subtypes and chemosensitivity in patients with DLBCL (all P <0.01). The expression of TUG1, stage of disease and tumor size influenced the overall survival of patients with DLBCL Factors of overall survival (OS). TUG1 expression, disease staging, IPI index and chemosensitivity are the factors affecting the prognosis of patients with DLBCL. Conclusion: The high expression of TUG1 in DLBCL tissue is an independent factor affecting the prognosis of patients. TUG1 may be a new prognostic marker in DLBCL patients and a potential target for DLBCL gene therapy.